Compare AMSF & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMSF | CTMX |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 630.9M | 596.2M |
| IPO Year | 1996 | 2015 |
| Metric | AMSF | CTMX |
|---|---|---|
| Price | $32.50 | $5.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $50.33 | $11.30 |
| AVG Volume (30 Days) | 165.9K | ★ 8.2M |
| Earning Date | 04-28-2026 | 03-16-2026 |
| Dividend Yield | ★ 8.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $317,252,000.00 | $76,201,000.00 |
| Revenue This Year | $8.06 | N/A |
| Revenue Next Year | $6.34 | $16.91 |
| P/E Ratio | ★ $13.26 | $22.58 |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $32.00 | $0.40 |
| 52 Week High | $53.27 | $8.21 |
| Indicator | AMSF | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 48.55 |
| Support Level | $32.00 | $4.92 |
| Resistance Level | $39.25 | $6.20 |
| Average True Range (ATR) | 0.92 | 0.61 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 0.00 | 16.63 |
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.